 |
|
|
| |
ACTG A5391: A Randomized Multicenter 3-arm Controlled Trial for People with Obesity on Integrase Inhibitors and Tenofovir Alafenamide switching to Doravirine, with or without Tenofovir Disoproxil Fumarate (The DO-IT Trial)
|
| |
| |
IAS 2025 July 13-17 Rwanda
John Koethe, MD
Vanderbilt University Medical Center, Nashville, TN, USA
COMMENT from Jules: They did not look at a switch to DOR early, say within 1 year:
"Median time on current INSTI+TAF/FTC was 3.4 years; 86% were taking BIC, 13% DTG, and 1% RAL, all with TAF/FTC."
|
| |
|
|
|
|
|
